Vaccine Breakthrough Infections with SARS-CoV-2 Variants.
Vaccine Breakthrough Infections with SARS-CoV-2 Variants.
复制标题
DOI：
10.1056/nejmoa2105000
复制
发表时间：
2021-06-10
期刊：
影响因子：
--
通讯作者：
Darnell RB
中科院分区：
文献类型：
--
作者：
Hacisuleyman E;Hale C;Saito Y;Blachere NE;Bergh M;Conlon EG;Schaefer-Babajew DJ;DaSilva J;Muecksch F;Gaebler C;Lifton R;Nussenzweig MC;Hatziioannou T;Bieniasz PD;Darnell RB
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的新变种引起临床关注。在至少两周前接种了第二剂BNT162b2(辉瑞-BioNTech)或mRNA-1273(莫德纳)疫苗的417人队列中，我们发现有2名妇女感染了疫苗突破性感染。尽管有证据表明疫苗对这两名女性有效，但2019年出现了冠状病毒病的症状，通过聚合酶链式反应检测，她们的SARS-CoV-2呈阳性。病毒测序发现了可能具有临床重要性的变异，包括1名女性的E484K和两人的三个突变(T95I、del142-144和D614G)。这些观察表明，在成功接种疫苗并随后感染变异病毒后，存在潜在的疾病风险，它们为继续努力预防和诊断感染并确定接种疫苗的人的变异特征提供了支持。(由美国国立卫生研究院和其他机构资助。)
Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are of clinical concern. In a cohort of 417 persons who had received the second dose of BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) vaccine at least 2 weeks previously, we identified 2 women with vaccine breakthrough infection. Despite evidence of vaccine efficacy in both women, symptoms of coronavirus disease 2019 developed, and they tested positive for SARS-CoV-2 by polymerase-chain-reaction testing. Viral sequencing revealed variants of likely clinical importance, including E484K in 1 woman and three mutations (T95I, del142–144, and D614G) in both. These observations indicate a potential risk of illness after successful vaccination and subsequent infection with variant virus, and they provide support for continued efforts to prevent and diagnose infection and to characterize variants in vaccinated persons. (Funded by the National Institutes of Health and others.)